Boston Scientific Corp. (BSX) Tops Q2 EPS by 7c; Guides Q3 EPS Below, Reaffirms FY12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BSX Hot Sheet
Price: $45.89 +5.49%
Financial Fact:
Net income (loss): 228M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Net income (loss): 228M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Boston Scientific Corp. (NYSE: BSX) reported Q2 EPS of $0.17, $0.07 better than the analyst estimate of $0.10. Revenue for the quarter came in at $1.83 billion versus the consensus estimate of $1.89 billion.
Boston Scientific Corp. sees Q3 2012 EPS of $0.14-$0.17, versus the consensus of $0.11. Boston Scientific Corp. sees Q3 2012 revenue of $1.725-$1.825 billion, versus the consensus of $1.83 billion.
Reaffirms FY12 outlook.
For earnings history and earnings-related data on Boston Scientific Corp. (BSX) click here.
Boston Scientific Corp. sees Q3 2012 EPS of $0.14-$0.17, versus the consensus of $0.11. Boston Scientific Corp. sees Q3 2012 revenue of $1.725-$1.825 billion, versus the consensus of $1.83 billion.
Reaffirms FY12 outlook.
For earnings history and earnings-related data on Boston Scientific Corp. (BSX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Berkshire Hathaway hits 52-week high on election rally
- Reynolds Consumer Products Inc. (REYN) Tops Q3 EPS by 1c, Beats on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
